Penn experts will present research findings that could come to define new standards of cardiovascular diagnostics and care at this weekends conference of the American College of Cardiology, the foremost professional society representing heart specialists throughout the world. These experts will gather beginning this weekend in Chicago to present and discuss the latest advances in cardiovascular medicine, science and education.
To arrange interviews with any of these presenters or other Penn physicians who will be in attendance, please call 215-200-2313, or email firstname.lastname@example.org. All research results are embargoed until the time they are presented during the conference.
The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients with Coronary Heart Disease or Risk Equivalent
Emile R. Mohler, MD, Director of Vascular Medicine and Associate Professor of Medicine
10 a.m., Sunday, March 30
Dr. Mohler will present results of a trial that may herald a new class of medications to prevent heart attack and stroke. Researchers at Penn and several other sites around the world studied the safety and efficacy of the drug darapladib (manufactured by GlaxoSmithKline) on Lp-PLA, an enzyme associated with inflammatory activity and increased risk for heart attack and stroke.
The drug was tested among patients already taking a cholesterol-lowering statin drug. After 12 weeks on a daily regimen of 160 mg of darapladib, blood tests revealed a decrease in two important circulating biomarkers, suggesting a possible reduction in systemic inflammatory burden.
While the drug doesnt necessarily act to shrink plaque, Mohler says the research suggests that darapladib may reduce plaque inflammation and therefore lower rates of clot formation and heart attacks among patients with coronary heart disease. <
|Contact: Holly Auer|
University of Pennsylvania School of Medicine